EnzymeBioSystems (OTCBB:ENZB) said that its preclinical ‘methyl Amooranin’ batch is close to completion. It is the lead pharmaceutical candidate of the company that is meant for prevention of breast cancer.
The management view
Gary Rojewski, the CEO of EnzymeBioSystems (OTCBB:ENZB), said that the company anticipates the preclinical batch Amooranin to be completed in coming period. He added that it positions company right on schedule to finish the required trials for submitting an IND application to the U.S. FDA. The in vivo mice testing and vitro laboratory results appear to be encouraging for the reduction of tumors with the help of methyl Amooranin.
In December, EnzymeBioSystems confirmed that preclinical xenograft trials with methyl Amooranin showed positive results in preventing human colon carcinoma. The testing method, Xenografting is a reliable and established preclinical method for evaluating anti-tumor therapies. It is a scientific method that features transplantation of tissue. In particular, transplantation of human tumor tissue into immuno-compromised mice worked as a better model than in vitro studies.
The study on anticancer effects of Methyl Amooranin in treating human colon carcinoma featured in the International Journal of Cancer in 2006. It stated that methyl Amooranin may be beneficial for the prevention of tumor growth. The product is a structurally modified form of a plant-based natural product. The Management of EnzymeBioSystems is in the development process of creating the required methyl Amooranin studies so that it can apply for an “IND” with the FDA.
The hopes are high
The successful completion of the trial will be a great accomplishment for the company following that it will seek the use of ‘Amooranin’ in the prevention of breast cancer. Rojewski said that as a precautionary statement, there is no guarantee that the company will ever get an IND for its potential compound. EnzymeBioSystems offers specialty enzyme related products in the industry.